Treatment of extended-spectrum beta-lactamase enterobacteriaceae with cefepime: The dose matters, too

Jerry Altshuler; Samuel L. Aitken; David Guervil; Diana Esaian; John Papadopoulos; Cesar A. Arias

doi:10.1093/cid/cit383

Treatment of extended-spectrum beta-lactamase enterobacteriaceae with cefepime: The dose matters, too

Jerry Altshuler, Samuel L. Aitken, David Guervil, Diana Esaian, John Papadopoulos, Cesar A. Arias

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	915-916
Number of pages	2
Journal	Clinical Infectious Diseases
Volume	57
Issue number	6
DOIs	https://doi.org/10.1093/cid/cit383
State	Published - Sep 15 2013

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1093/cid/cit383

Cite this

@article{97086a89d862490f9e8581ead2ffb1fd,

title = "Treatment of extended-spectrum beta-lactamase enterobacteriaceae with cefepime: The dose matters, too",

author = "Jerry Altshuler and Aitken, {Samuel L.} and David Guervil and Diana Esaian and John Papadopoulos and Arias, {Cesar A.}",

note = "Funding Information: ceived research support from Forest Laboratories and has served as an advisor for Cubist. C. A. A. is a consultant for Pfizer and Cubist; has received grants from Pfizer, Forest Pharmaceuticals, and Therav-ance; and has received payment for lectures from Pfizer, Cubist, Forest Pharmaceuticals, and Novar-tis. All other authors report no potential conflicts.",

year = "2013",

month = sep,

day = "15",

doi = "10.1093/cid/cit383",

language = "English (US)",

volume = "57",

pages = "915--916",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "6",

}

TY - JOUR

T1 - Treatment of extended-spectrum beta-lactamase enterobacteriaceae with cefepime

T2 - The dose matters, too

AU - Altshuler, Jerry

AU - Aitken, Samuel L.

AU - Guervil, David

AU - Esaian, Diana

AU - Papadopoulos, John

AU - Arias, Cesar A.

N1 - Funding Information: ceived research support from Forest Laboratories and has served as an advisor for Cubist. C. A. A. is a consultant for Pfizer and Cubist; has received grants from Pfizer, Forest Pharmaceuticals, and Therav-ance; and has received payment for lectures from Pfizer, Cubist, Forest Pharmaceuticals, and Novar-tis. All other authors report no potential conflicts.

PY - 2013/9/15

Y1 - 2013/9/15

UR - http://www.scopus.com/inward/record.url?scp=84883242242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883242242&partnerID=8YFLogxK

U2 - 10.1093/cid/cit383

DO - 10.1093/cid/cit383

M3 - Letter

C2 - 23784927

AN - SCOPUS:84883242242

SN - 1058-4838

VL - 57

SP - 915

EP - 916

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 6

ER -

Treatment of extended-spectrum beta-lactamase enterobacteriaceae with cefepime: The dose matters, too

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this